Search

A 10-day course of penicillin is the antibiotic regimen currently recommended by the American Heart Association (AHA) as treatment for patients with tonsillitis caused by group A β-haemolytic streptococci (GABHS), with the aim of preventing both the suppurative and non-suppurative complications of this infection. This prospective, multicentre, randomized, double-blind, double-dummy clinical trial was undertaken in order to compare the efficacy of, tolerability of and compliance with a 5-day course ofcefotiam hexetil (CTM) 200 mg bd with that of 10-day course of penicillin V (PEV) I megaunit (600 mg) tds, to investigate the significance of recovering GABHS during or after treatment and to evaluate the potential economic advantages of short-term regimens. Two hundred and fifty ambulatory adult patients with a presumptive diagnosis (based on a positive rapid antigen detection test) of GABHS tonsillitis were recruited in 60 centres ; the diagnosis was subsequently confirmed by a positive culture of a throat swab. At the time of entry into the trial there was no statistically significant difference between the groups in terms of clinical symptoms. In an intention-to-treat analysis, both the clinical and bacteriological response rates at days 10 and 30 were comparable for each group i.e. 106 of 119 (89.1%) patients and 90 of 109 (82.6%) patients respectively in the CTM group and 103 of 117 (88.0%) patients and 92 of 107 (86.0%) patients respectively in the PEV group. The times until defervescence and resolution of symptoms were also similar. Of the 115 patients in each group who were assessed at day 90, there were three clinical relapses in the CTM group and seven in the PEV group. No non-suppurative complications of GABHS infection were detected. Tolerance was significantly better in the CTM group than in the PEV group, 14 of 119 (11.8%) patients and 26 of 117 (22.2%) patients in the former and latter groups respectively reporting adverse events. In three cases in each group treatment was discontinued prematurely because of adverse events ; none of these in the CTM group was serious but one patient in the PEV group experienced a severe allergic reaction. Compliance in both groups was good during the first 5 days of therapy but, by the end of each course, 93.6% of patients in the CTM group had completed treatment, compared with 73.0% in the PEV group. Time lost from work was noted in respect of 68.0% ofpatients who were gainfully employed and prolonging treatment from 5 to 10 days would have led to a mean increase in the time away from work of 1.7 days. In conclusion, a 5 day course of cefotiam hexetil was shown to be effective and safe therapy for patients with GABHS tonsillitis. However, a more accurate estimate of the cost-effectiveness of this regimen will be required before AHA recommendations can be revised.

Medical decisions have to integrate not only the clinical dimension of a disorder, but also all the repercussions of the therapeutic strategy on the patient's life. Various techniques may be used to identify the preferences of a subject, by estimating the relative utility associated with different states of health. One of these techniques, the "standard gamble", enabled us to determine the utility that patients with recurrent respiratory infections associate with the results of various therapies. The findings show that this utility is not a linear function of therapeutic results. They also show that when the number of years of lost life is calculated, the loss due to alteration of the quality of life linked to the frequency of acute episodes is not obstructive pulmonary disease.